Whalesbook
Board Approves Bonus Shares and Capital Boost
Biogen Pharmachem's board has approved a proposal for a 1:6 bonus share issue, which will increase the company's authorized share capital from ₹91 crore to ₹108 crore.
Key Decisions Made
The Board of Directors of Biogen Pharmachem Industries Limited met on March 23, 2026, approving a bonus share issuance in a 1:6 ratio. This means shareholders will receive one new bonus share for every six shares they currently own.
The issuance of 15,04,33,833 shares will be funded from the company's share premium reserve. The authorized share capital will also be increased from ₹91 crore to ₹108 crore to support this growth.
Separately, M/s. Goenka Mehta & Associates have been appointed as the company's new statutory auditors.
What the Decisions Mean for Investors
Bonus shares are additional shares given to existing shareholders at no cost. This increases the total number of shares outstanding without changing a shareholder's ownership percentage.
This move can be viewed favorably by the market, potentially improving share liquidity and investor interest.
Raising the authorized share capital is necessary for issuing more shares and may signal future growth initiatives or employee incentive plans.
The appointment of new auditors is a standard procedure that can bring a new view to financial reporting and controls.
Company Background and Recent Performance
Biogen Pharmachem, established in 1995, operates as a Non-Banking Financial Company (NBFC) primarily involved in trading shares and securities.
This is the first bonus share issuance for the company since at least January 2000, marking a significant point in its corporate history.
Financially, the company has shown recovery, posting a net profit of ₹1.34 crore for the quarter ending December 2025, a notable improvement from a loss in the same period last year.
Immediate Impacts of the Decisions
- Shareholders will receive additional shares, increasing their holdings by one for every six they own, without any cost.
- The overall number of Biogen Pharmachem's outstanding shares will increase significantly.
- The company's authorized share capital will be expanded to ₹108 crore.
- M/s. Goenka Mehta & Associates will now serve as the statutory auditors.
Key Risks and Hurdles
The main obstacle for both the bonus share issue and the authorized capital increase is obtaining shareholder approval via a postal ballot.
Industry Trends and Peer Actions
The bonus share issuance follows a trend seen among other Indian companies. Metropolis Healthcare Ltd. completed a 3:1 bonus issue in March 2026, while Kilitch Drugs India Ltd. and Times Green Energy (India) Ltd. announced 1:1 bonus ratios recently.
Biogen Pharmachem's 1:6 bonus ratio represents a larger proportion of new shares compared to some peers, potentially leading to a more substantial increase in share count for its investors.
Key Financial Context
- Paid-up equity share capital was ₹90.26 crore as of Q1 FY26 (ended December 2025).
- Net profit for the quarter ending December 2025 was ₹1.34 crore.
Next Steps for Investors to Monitor
- The results of the shareholder vote on the bonus share issue and capital change via postal ballot.
- The official record date for bonus share eligibility.
- The timing of bonus shares being credited to shareholder demat accounts, usually within two months of approval.
- Any future announcements or reports from the new statutory auditors, M/s. Goenka Mehta & Associates.